Literature DB >> 3121382

Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor.

P M Mannucci1, G Tamaro, G Narchi, G Candotti, A Federici, D Altieri, F Tedesco.   

Abstract

A 16-yr-old girl with severe von Willebrand disease complicated by the development of precipitating alloantibodies to von Willebrand factor (anti-VWF) had a life-threatening anaphylactoid reaction immediately after the infusion of a commercial plasma concentrate of factor VIII/von Willebrand factor. An early post-infusion activation of the complement system was demonstrated by the appearance of C3 split products and by the drop of serum CH50 activity, occurring in parallel with a post-infusion drop in the anti-VWF antibody levels. Immune complexes remained unchanged in the early post-infusion period and rose to a moderate extent only after 24 h. We conclude that biologically active products of the complement system contributed to the onset of this life-threatening reaction which occurred after concentrate infusion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3121382     DOI: 10.1111/j.1600-0609.1987.tb01458.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  12 in total

1.  Clinical and laboratory versus molecular markers for a correct classification of von Willebrand disease.

Authors:  Augusto B Federici; Maria T Canciani
Journal:  Haematologica       Date:  2009-05       Impact factor: 9.941

2.  Some characteristics of aggregates of IgG and plasma proteins in heat-treated factor VIII concentrates.

Authors:  C Wadsworth; L A Hanson; H Kjellman; T Söderström; M Blombäck
Journal:  Blut       Date:  1989-03

Review 3.  Alloantibodies in von Willebrand disease.

Authors:  Paula D James; David Lillicrap; Pier M Mannucci
Journal:  Blood       Date:  2013-01-07       Impact factor: 22.113

4.  Factor VIII-mediated global hemostasis in the absence of von Willebrand factor.

Authors:  Masahiro Takeyama; Shogo Kasuda; Yoshihiko Sakurai; Midori Shima; Tomohiro Takeda; Shoko Omura; Hiroyuki Naka; Akira Yoshioka
Journal:  Int J Hematol       Date:  2007-06       Impact factor: 2.490

5.  Evidence-based recommendations on the treatment of von Willebrand disease in Italy.

Authors:  Pier Mannuccio Mannucci; Massimo Franchini; Giancarlo Castaman; Augusto B Federici
Journal:  Blood Transfus       Date:  2009-04       Impact factor: 3.443

Review 6.  Current management of von Willebrand's disease.

Authors:  G Castaman; F Rodeghiero
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

7.  Successful Desensitization of a Patient with Possible IgE-Mediated Anaphylactic Reaction to FVIII/VWF Concentrate.

Authors:  Burcin Beken; Velat Celik; Pinar Gokmirza Ozdemir; Tuba Eren; Mehtap Yazicioglu
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2019-06-17       Impact factor: 1.349

Review 8.  Principles of care for the diagnosis and treatment of von Willebrand disease.

Authors:  Giancarlo Castaman; Anne Goodeve; Jeroen Eikenboom
Journal:  Haematologica       Date:  2013-05       Impact factor: 9.941

Review 9.  The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology.

Authors:  Mike A Laffan; Will Lester; James S O'Donnell; Andrew Will; Robert Campbell Tait; Anne Goodeve; Carolyn M Millar; David M Keeling
Journal:  Br J Haematol       Date:  2014-08-12       Impact factor: 6.998

10.  Monitoring of von Willebrand factor inhibitors in patients with type 3 von Willebrand disease using a quantitative assay.

Authors:  Connie H Miller
Journal:  Haemophilia       Date:  2021-06-05       Impact factor: 4.263

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.